Yi Shi is the Founder and Managing Partner of Lilly Asia Ventures, a leading biomedical venture capital firm with focus on China. Prior to his current role, Yi worked at Eli Lilly and Company in business development licensing and corporate ventures. His education includes a Ph.D. in Biochemistry and a Master of Business Administration, both from Duke University. He also has a B.S. in Biology from the University of Science and Technology of China. His past and current Board memberships include: Betta Pharmaceuticals, Innovent Biologics, Chipscreen Biosciences, and Elpiscience.